R3R

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

medical-cross
Chronic kidney disease
user
All genders
person-wave 12+
world
Recruiting now
More information  

Overview
Principal Investigator: Lesley Inker

The purpose of this Phase II trial is to see if R3R01 is safe in patients with Alport Syndrome and Focal Segmental Glomerulosclerosis. This will be done by evaluating how efficient R3R01 is in decreasing proteinuria levels. 

The study will consist of a screening period, a treatment period, and a follow-up period. If you qualify, you will receive the study drug R3R01 for 12 weeks. We will then follow up with you after for an additional 12 weeks.

Study details
Inclusion Criteria
  • Age 12 years or older
  • Diagnosis of Alport Syndrome (confirmed by genetic testing and/or kidney biopsy) / Primary FSGS (confirmed by renal biopsy)
Exclusion Criteria
  • Uncontrolled diabetes mellitus or hypertension
  • History of organ transplant or possibility of transplant in the six months after screening
  • If you aren't sure if you qualify, please call us and we will help determine your eligibility.
Study Requirements

If you qualify, you will receive R3R01 for 12 weeks. We will then follow up with you for an additional 12 weeks following completion of the study drug treatment.